Bollard Group LLC Buys 7,658 Shares of Merck & Co., Inc. $MRK

Bollard Group LLC lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 4.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 173,367 shares of the company’s stock after purchasing an additional 7,658 shares during the quarter. Bollard Group LLC’s holdings in Merck & Co., Inc. were worth $14,551,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of MRK. Brighton Jones LLC boosted its stake in Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares during the period. Sivia Capital Partners LLC raised its stake in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the period. Advisors Capital Management LLC lifted its holdings in shares of Merck & Co., Inc. by 9.8% in the 2nd quarter. Advisors Capital Management LLC now owns 145,910 shares of the company’s stock worth $11,550,000 after acquiring an additional 13,036 shares during the last quarter. Beacon Harbor Wealth Advisors Inc. purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $6,205,000. Finally, Foundations Investment Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 10.6% during the 2nd quarter. Foundations Investment Advisors LLC now owns 26,831 shares of the company’s stock worth $2,124,000 after purchasing an additional 2,565 shares during the period. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday. Guggenheim upped their target price on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Zacks Research downgraded Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Friday, January 9th. UBS Group boosted their price objective on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Royal Bank Of Canada began coverage on Merck & Co., Inc. in a research report on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $126.81.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $115.61 on Friday. The firm’s 50 day simple moving average is $115.26 and its 200-day simple moving average is $99.68. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The firm has a market cap of $285.84 billion, a PE ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Insider Activity

In related news, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the sale, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Robert M. Davis sold 47,434 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the sale, the chief executive officer directly owned 443,602 shares of the company’s stock, valued at approximately $52,362,780.08. This trade represents a 9.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Company insiders own 0.13% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.